Regeneus Ltd. announced that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company. John will continue to serve on the Board as a non-executive director.

Leo joined the Board as an independent non-executive director in December 2017. Leo will lead the Company's ongoing efforts to secure first major clinical licence of Progenza in Japan.